Verrica Pharmaceuticals

Verrica's business model centers on generating revenue through the sale of its approved products while advancing its pipeline candidates through clinical trials toward regulatory approval. The company's primary market is medical dermatology, targeting conditions with significant unmet needs. Verrica's first major achievement was the FDA approval of its lead product, YCANTH™ (formerly VP-102), on July 21, 2023, making it the first approved treatment for molluscum contagiosum in the U.S. This highly contagious viral skin infection primarily affects children and previously had no FDA-approved therapies. The company projects net product revenues between $48 million and $55 million for fiscal year 2024, signaling its transition to a commercial-stage entity.

YCANTH™ is a proprietary drug-device combination product. It delivers a controlled formulation of cantharidin, a naturally sourced vesicant, through a single-use precision applicator designed for targeted administration by a healthcare professional. This method is intended to enhance safety and efficacy compared to previous unapproved formulations. The approval was based on positive results from two Phase 3 clinical trials, CAMP-1 and CAMP-2, which demonstrated a significantly higher rate of complete lesion clearance compared to placebo in patients aged two and older. Beyond molluscum, Verrica is developing YCANTH™ for the treatment of common warts and external genital warts. The company's pipeline also includes VP-103 for plantar warts and VP-315, a potential treatment for certain skin cancers.